Liposomal Irinotecan and Apatinib
Phase 2Small molecule
Liposomal Irinotecan and Apatinib is one of 48 small molecule programs targeting Breast Cancer. It is currently in Phase 2.
3
Indications
4
Total Trials
3
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Adenocard
AstellasPreclinical
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Liposomal Irinotecan and Apatinib
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Tricor
JJagotec
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Ablavar
LLantheus Medical Imaging
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Apatinib1 trial
Liposomal Irinotecan and Apatinib in ES-SCLC
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06749691·30 enrolled
Postoperative Analgesia1 trial
Effect of Local Infiltration of Liposomal Bupivacaine on Postoperative Analgesia in Patients With Craniotomy Microvascular Decompression
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT07245290·100 enrolled
Breast Cancer1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details